EDSA - Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Edesa Biotech (EDSA) has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b study evaluating its lead product candidate, EB01 cream as a monotherapy for chronic allergic contact dermatitis.The 46-subject study is evaluating the safety and efficacy of the drug candidate.EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor.Allergic contact dermatitis is a form of dermatitis/eczema caused by an allergic reaction to a material, in contact with the skin.Shares are up 6% in premarket on light volume.

For further details see:

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment